• 87% of respondents already hold digital assets in their investment portfolios, with nearly half allocating more than 10% to digital assets

• 57% of HNWIs – and 61% of UHNWIs – have a bullish or very bullish long-term crypto market outlook, a view supported by the accelerating crypto and TradFi industry integration

• 80% want ETFs beyond Bitcoin and Ethereum, with Solana (52%) showing the next highest demand. 70% would allocate or increase allocations if staking yield were included

• 66% say their private bank or wealth manager needs to demonstrate high custody and security standards to enable them to invest confidently in digital assets

SINGAPORE, Dec. 11, 2025 /PRNewswire/ — Sygnum Singapore today releases its APAC HNWI Report 2025, revealing through a survey that Asian private wealth has moved decisively into digital assets—and now expects traditional wealth managers to catch up. The survey of over 270 HNWIs and professional investors across 10 APAC markets comes as nearly half of respondents’ crypto allocations go past the 10% mark, with median HNWI holdings in the 10–20% range.

From speculation to wealth preservation

The report shows a maturation in how Asian private wealth approaches digital assets. An overwhelming 90% of surveyed HNWIs view digital assets as important for long-term wealth preservation and legacy planning—not purely speculation. Portfolio diversification now drives 56% of investment decisions, overtaking short-term trading and megatrend exposure.

Their disciplined approach is evident; HNWIs showed stronger interest in actively managed exposure, outsourced mandates and even yield strategies. The emphasis is on integration with existing wealth structures, not isolated positions.

“Digital assets are now firmly embedded within APAC’s private wealth ecosystem. Singapore’s MAS framework and Hong Kong’s advancing digital asset regulations have established the infrastructure needed for traditional wealth managers to offer crypto services—the question is no longer whether private banks can serve this demand, but when they will move to meet it. Despite near-term macro uncertainty, we continue to see accelerating adoption driven by strategic portfolio diversification, intergenerational wealth planning, and demand for institutional-grade products. APAC is rapidly becoming one of the world’s fastest growing and most important digital asset gateways, and we expect this momentum to strengthen further into 2026.” says Gerald Goh, Sygnum Co-Founder and APAC CEO.

Strong appetite for ETFs and yield-enhanced products

Beyond Bitcoin and Ethereum, 80% of APAC HNWI investors want access to additional digital asset ETFs. Solana has the next highest demand at 52%, followed by strong interest in multi-asset index products (48%) and XRP (41%). 70% say they would allocate or increase allocations if staking yield were included in ETF products—underscoring APAC’s preference for yield-enhanced, regulated investment vehicles that can integrate seamlessly with traditional portfolios.

Cautious near-term outlook, strong long-term conviction

While 60% plan to increase allocations, many investors are timing entries cautiously following recent market corrections. Regulatory uncertainty, custody and security concerns, as well as differing regional licensing frameworks, remain key barriers to increased participation. Nonetheless, long-term conviction remains strong, supported by rising on-chain activity, a growing ETF ecosystem, and clearer regulatory pathways.

“HNWIs in Singapore and the wider APAC region are embracing digital assets as a genuine wealth creation and preservation opportunity. Their disciplined, intergenerational approach to investing, combined with a higher risk appetite, is driving substantial allocations to digital assets—particularly within Singapore’s well-regulated MAS framework that provides the institutional-grade safeguards these investors expect,” says Lucas Schweiger, report author and Sygnum Crypto Asset Ecosystem Research Lead.

About the report

Sygnum’s APAC HNWI Report 2025 surveyed more than 270 high-net-worth and professional investors (95% were independent market participants) across 10 Asia-Pacific markets including Singapore, Hong Kong SAR, Indonesia, South Korea and Thailand. Over half the respondents have more than a decade of investment experience, with 20% active for more than 20 years. The findings reveal a rapidly maturing private wealth segment that is integrating digital assets as a core component of long-term wealth and portfolio strategy.

About Sygnum

Sygnum is a global digital asset banking group, founded on Swiss and Singapore heritage. We empower professional and institutional investors, banks, corporates and DLT foundations to invest in digital assets with complete trust. Our team enables this through our institutional-grade security, expert personal service and portfolio of regulated digital asset banking, asset management, tokenization and B2B services. 

In Switzerland, Sygnum holds a banking license and has CMS and Major Payment Institution licences in Singapore. The group is also regulated in the established global financial hubs of Abu Dhabi and Luxembourg and is registered in Liechtenstein.

We believe that the future has heritage. Our crypto-native team of banking, investment and digital asset technology professionals are building a trusted gateway between the traditional and digital asset economies that we call Future Finance. To learn more about how Sygnum’s mission and values are shaping this digital asset ecosystem, please visit sygnum.com/sg and follow us on LinkedIn and X.

© 2025 Sygnum –all rights reserved. The information in this publication pertaining to Sygnum Pte. Ltd. (“Sygnum”) is for general information purposes only, as per date of publication, and should not be considered exhaustive. This publication does not consider the financial situation of any natural or legal person, nor does it provide any tax, legal or investment advice. This publication does not constitute any advice or recommendation, an offer or invitation by or on behalf of Sygnum to purchase or sell any assets. No elements of precontractual or contractual relationship are intended. While the information is believed to be from accurate and reliable sources, Sygnum makes no representation or warranties, expressed or implied, as to the accuracy of the information. Sygnum expressly disclaims any and all liability that may be based on such information, omissions, or errors thereof. Any statements contained in this publication attributed to a third party represent Sygnum’s interpretation of the data, information and/or opinions provided by that third party either publicly or through a subscription service, and such use and interpretation have not been reviewed by the third party. Sygnum reserves the right to amend or replace the information, in part or entirely, at any time, and without any obligation to notify the recipient of such amendment / replacement or to provide the recipient with access to the information. Simultaneously, there is no obligation of Sygnum to inform recipients of information, if before provided information later becomes outdated, inaccurate or obsolete, unless otherwise provided by applicable law. The information provided is not intended for use by or distributed to any individual or legal entity in any jurisdiction or country where such distribution, publication or use would be contrary to the law or regulatory provisions or in which Sygnum does not hold the necessary registration, approval authorization or license. Except as otherwise provided by Sygnum, it is not allowed to modify, copy, distribute or reproduce, display, license, or otherwise use any content for commercial purposes. You can find out more about how Sygnum processes your personal data in our privacy notice here.

HONG KONG, Dec. 11, 2025 /PRNewswire/ — Hakka medicine is the result of deep integration between traditional Central Plains Chinese medicine and the natural environment of southern China, carrying profound historical heritage and unique clinical value. The  Seventh World Hakka Entrepreneurs Convention was held in Meizhou, Guangdong from November 23 to 25. With the theme of “Gather Global Hakka Entrepreneurs • Facilitate High-Quality Development”, the conference upheld the principles of “openness, innovation, cooperation, and mutual benefit,” and explored new opportunities for the development of Hakka culture and industrial development. At this grand, globally watched event, Guangdong Jiaying Pharmaceutical Co., Ltd. showcased its star products, including “Double-ingredient Throat Wind Relief Powder” (Double-ingredient Throat Wind Relief Powder), “Gujing Shenrong Wan” (Solid Essence Ginseng and Antler Pill), and “Longnao Gao” (Borneol Ointment), presenting the unique charm of Hakka medicine to the world.

At present, companies such as Jiaying Pharmaceutical in Guangdong, China, are actively advancing the industrialization of Hakka medicine through industry-academia-research collaboration, dosage-form improvement, and supply-chain integration. Meanwhile, Hakka medicine is also striving to re-enter overseas markets, aiming to build internationally influential health brands.

Millennia of Heritage: The Historical Depth and Unique Value of Hakka medicine 

Hakka medicine originated from the southward migration of Han people from the Central Plains and gradually developed a distinctive theoretical system through the integration of indigenous southern medical knowledge. Throughout Chinese history, Hakka medicine witnessed the emergence of many representative figures and classic formulations. During the Jiaqing period of the Qing Dynasty, Lu Zengxiong, a senior Hakka physician from Yongding, Fujian, developed Wanying Tea by integrating folk prescriptions from traveling physicians in Jiangxi. In 2008, Wanying Tea was listed as a National Intangible Cultural Heritage; in 2012, it obtained National Geographical Indication Product Protection, becoming an iconic representative of Hakka medicine in Fujian.

Aw Boon Haw became known as the “King of Tiger Balm” and the “Newspaper King.” In 1910, he successfully developed five portable proprietary medicines, including Tiger Balm and Eight Diagrams Pill. With a low-profit, high-volume strategy, Haw Par Tiger Balm quickly became popular across Southeast Asia. Through newspaper promotion and public welfare projects, Hu enhanced brand credibility and successfully brought Haw Par medicine to the international market, becoming one of the pioneers of Hakka medicine’s global expansion.

Technology Empowerment: The Pathway to Industrialization 

The core of industrializing Hakka medicine lies in transforming traditional formulations into modern pharmaceutical products, with technological improvement and innovation being especially critical.

Take Jiaying Pharmaceutical’s Double-ingredient Throat Wind Relief Powder as an example. Originating from a verified Qing Dynasty prescription, this product has a history of more than 170 years. Containing ingredients such as pearl and artificial bezoar, it provides heat-clearing and detoxifying effects. During industrialization, the company optimized the extraction process and converted the powder into a spray formulation, significantly improving user experience.

In research and development, domestic Hakka medicine companies actively collaborate with universities and research institutions. 

Industrial Chain Integration: Comprehensive Industrial Layout 

The industrialization of Hakka medicine relies on full-chain integration and coordinated development. As the “World Hakka Capital,” Meizhou has already taken significant steps in this process.

In the planting stage, Meizhou has leveraged its selenium-rich soil and abundant traditional Chinese medicinal resources, comprising more than 1,800 medicinal herb species, including 282 nationally and provincially designated key varieties, accounting for 61% of all surveyed species, to establish multiple industrialized cultivation bases for Chinese medicinal materials.

In the research and development stage, Meizhou has built a relatively comprehensive scientific research platform system, with seven provincial-level traditional Chinese medicine (TCM) engineering technology research centers, nine municipal-level engineering technology research centers, three national master TCM heritage studios, and three innovation and entrepreneurship team projects related to traditional Chinese medicine introduced under Guangdong Province’s “Sailing Program.”

In the production stage, Hakka medicine enterprises have actively enhanced quality control through GMP certification and have developed digital factories that integrate automation, informatization, and intelligent manufacturing in traditional Chinese medicine production.

In the sales stage, Meizhou Jiaying Pharmaceutical’s Double-ingredient Throat Wind Relief Powder has been vigorously expanding its presence in offline pharmacies, now covering more than 300,000 retail terminals across China and capturing one-half of the national terminal market share.

In terms of cultural promotion, Hakka medicine is actively exploring an integrated “medicine + tourism” model.

Cultural Globalization: International Experience and Strategies 

A century later, Hakka medicine companies, represented by Jiaying Pharmaceutical, are actively expanding into international markets by establishing the wholly owned subsidiary Jiaying International to strengthen commercial channels. In February 2025, the first batch of Double-ingredient Throat Wind Relief Powder was successfully exported to Hong Kong, marking a crucial step in the overseas expansion of this patented TCM. In the second half of 2024, under customs supervision, a batch of Chinese medicinal materials, including chrysanthemum, rhizoma anemarrhenae, and lalang grass rhizome, totaling three varieties and weighing 100 kilograms, was successfully exported by a local Meizhou enterprise, marking the first export of Meizhou’s Chinese medicinal materials.

The industrialization of Hakka medicine not only represents the inheritance and innovation of TCM but also embodies the continuation and promotion of the Hakka cultural spirit. Today, Hakka medicine enterprises are advancing industrialization through technological upgrades, dosage-form innovation, and supply-chain integration, while also developing a “product + culture” dual marketing model to actively enter Southeast Asian and Western markets. Hakka medicine continues to demonstrate renewed vitality throughout its historical evolution.

In its future development, Hakka medicine is poised to become an important bridge for cooperation in the health sector between China and the rest of the world, contributing more “Chinese wisdom” to global health. Hakka medicine is embarking on a uniquely distinctive path toward industrial development, giving full play to the value of traditional wisdom in modern society.

SYDNEY, Dec. 11, 2025 /PRNewswire/ — Razor Labs (TASE:RZR) announces the launch of DataMind AI™ 4.5, a powerful upgrade to its predictive maintenance platform designed for mobile fleet management and fixed assets across mining operations. Built through continuous collaboration with dozens of global mining sites, Version 4.5 delivers clearer diagnostics, faster insights, and stronger visibility for maintenance and reliability teams.

“Version 4.5 was shaped together with dozens of mining sites operating a wide variety of mobile fleets and fixed assets,” said Raz Roditti, CEO. “It delivers exactly what maintenance teams need: clearer visibility, faster diagnostics, and stronger predictive maintenance capabilities.”

Advanced Diagnostics Environment for Mining

The new version provides engineers with a unified view of asset health, combining fault diagnostics derived from sensor health data with maintenance information. By bringing everything together, teams can pinpoint root causes faster and take action sooner.

Full Raw Sensor Data Access for True Engineering Transparency

Version 4.5 now provides full access to raw vibration, oil, temperature, and pressure data, along with advanced envelope RMS and full-spectrum insights, including harmonics and sidebands. This enriched health data foundation supports deeper, more accurate fault diagnostics and asset health assessments for reliability engineers.

For reliability engineers, this means deeper condition monitoring, more accurate diagnostics, improved failure prediction, and higher confidence for maintenance decisions.

This makes DataMind AI™ one of the most advanced predictive maintenance and fleet monitoring platforms in the mining industry.

Faster Investigations Across the Entire Mine

With upgraded thresholds, flexible alarm filtering, enhanced work-order visibility, and stronger links to investigation workflows, DataMind AI™ 4.5 improves day-to-day monitoring and accelerates issue resolution. Improved sensor search, timestamp comparison, and smoother navigation help teams understand events and validate equipment issues in minutes, speeding up investigations and reducing unplanned downtime across both mobile fleets and fixed plant assets.

Together, these improvements deliver a highly precise and configurable monitoring and alarm system among predictive maintenance solutions.

Fully Connected Predictive Maintenance Ecosystem

DataMind AI™ 4.5 combines raw sensor intelligence, full diagnostics, advanced alarm management, fault aggregation, AI insights, and maintenance history into one seamless experience.

These improvements make DataMind AI™ a predictive maintenance platform that delivers deep insights, transparency, and cross-asset connectivity across mobile fleets and fixed assets across the industry.

“We focused on the improvements that create the greatest impact in the field,” added Assaf Eden, VP Product. “DataMind AI 4.5 gives reliability engineers a simpler, more powerful way to manage the vast amount of sensor data in reliability, delivering clearer asset health visibility across all mining equipment. This enables fast work from investigation to maintenance actions, ensuring issues are resolved sooner, and operations stay productive.”

DataMind AI™ 4.5 is now available for all customers globally, supporting predictive maintenance for mobile fleets and fixed industrial assets.

To request a demo, visit www.razor-labs.com.

About Razor Labs

Razor Labs (TASE: RZR) is a global leader in mining technology, specializing in predictive maintenance solutions powered by advanced AI Sensor Fusion for Mobile Fleet, Fixed Assets, and Visual AI. With operations across Australia, South Africa, the United States, and Colombia, Razor Labs enables industrial teams to elevate reliability, efficiency, and safety.

Follow us on LinkedIn. Subscribe to our YouTube Channel.

Media inquiries: Ms. Liel Anisenko at pr@razor-labs.com or +972 (03) 561-0901